Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037635
Status:
COMPLETED
Last Update Posted:
2013-05-08
First Post:
2002-05-17
Brief Title:
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent AMG 073 in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism The study will look at the effects on parathyroid hormone calcium and phosphorus levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None